Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Novel Silicon-Based Fluorescent Nanocomposite Drug Carriers for Natural Compound Delivery in Melanoma Treatment

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Publication Information:
      Springer Science and Business Media LLC, 2025.
    • Publication Date:
      2025
    • Abstract:
      Melanoma, a highly aggressive cancer, is closely associated with an elevated tumor mutation burden (TMB) and an active tumor microenvironment (TME). Melanin synthesis, a key feature of melanoma progression, is primarily regulated by tyrosinase (TYR), the rate-limiting enzyme controlled by the microphthalmia-associated transcription factor (MITF). Resveratrol (Res), a natural polyphenol known for its antioxidant and anticancer properties, faces limitations including poor solubility, low bioavailability, and rapid metabolism. To overcome these challenges, a three-dimensional Co(II) coordination polymer {[Co(bpdado)(bpe)(H₂O)₂]·2DMF·2 H₂O}n (1) was synthesized and incorporated into a composite material, 1@CP1, for Res delivery (1@CP1@Res). The system exhibited enhanced solubility, pH-sensitive release, and improved biological activity. Fluorescence assays demonstrated significant quenching in the presence of Cu²⁺ ions, indicating a high sensitivity of 1@CP1@Res to metal ion interactions. The pH-responsive drug release profile was confirmed by in vitro studies showing accelerated release at lower pH values, mimicking the acidic tumor microenvironment. Cell viability assays revealed that 1@CP1@Res significantly inhibited the proliferation of murine B16-F10 melanoma cells, with cell survival rates of 72.4%, 58.2%, and 43.6% at 24, 48, and 72 h of incubation, respectively, at a concentration of 100 µM. Molecular docking studies further revealed multiple binding interactions between Res and the coordination polymer, suggesting a promising therapeutic strategy for melanoma treatment by integrating advanced materials with bioactive compounds.
    • ISSN:
      1573-4994
    • Accession Number:
      10.1007/s10895-025-04182-5
    • Rights:
      Springer Nature TDM
    • Accession Number:
      edsair.doi.dedup.....20339cab69ce16ca5f7c290553fcabdd